Predictive Oncology Inc Stock News

Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value

PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY.

Predictive Oncology Inc. (NASDAQ:POAI ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executive Officer Josh Blacher – Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conf...

Company to host investor call and webcast today, August 14th, at 8:30am EDT Company to host investor call and webcast today, August 14th, at 8:30am EDT

PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enabl...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 20...

Shares of biotechnology specialist Predictive Oncology (NASDAQ: POAI ) — which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols — soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer.

Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology